NEKTAR THERAPEUTICSNEKTAR THERAPEUTICSNEKTAR THERAPEUTICS

NEKTAR THERAPEUTICS

No trades
See on Supercharts
Market capitalization
‪4.14 B‬MXN
−24.73MXN
‪−4.69 B‬MXN
‪1.53 B‬MXN
‪177.94 M‬
Beta (1Y)
0.43

About NEKTAR THERAPEUTICS

CEO
Howard W. Robin
Headquarters
San Francisco
Website
Employees (FY)
137
Founded
1990
ISIN
US6402681083
FIGI
BBG00PBD0CZ8
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NKTR is 51.11 MXN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange NEKTAR THERAPEUTICS stocks are traded under the ticker NKTR.
NEKTAR THERAPEUTICS is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
NKTR stock is 0% volatile and has beta coefficient of 0.43. Check out the list of the most volatile stocks — is NEKTAR THERAPEUTICS there?
One year price forecast for NEKTAR THERAPEUTICS has a max estimate of 84.78 MXN and a min estimate of 16.96 MXN.
NKTR earnings for the last quarter are −4.18 MXN per share, whereas the estimation was −3.46 MXN resulting in a −21.02% surprise. The estimated earnings for the next quarter are −3.57 MXN per share. See more details about NEKTAR THERAPEUTICS earnings.
NEKTAR THERAPEUTICS revenue for the last quarter amounts to ‪420.85 M‬ MXN despite the estimated figure of ‪370.65 M‬ MXN. In the next quarter revenue is expected to reach ‪363.96 M‬ MXN.
Yes, you can track NEKTAR THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
NKTR net income for the last quarter is ‪−714.72 M‬ MXN, while the quarter before that showed ‪−798.97 M‬ MXN of net income which accounts for 10.55% change. Track more NEKTAR THERAPEUTICS financial stats to get the full picture.
Today NEKTAR THERAPEUTICS has the market capitalization of ‪4.14 B‬, it has decreased by 2.51% over the last week.
No, NKTR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NKTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEKTAR THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
NKTR reached its all-time high on Jul 11, 2019 with the price of 681.01 MXN, and its all-time low was 43.40 MXN and was reached on Jan 23, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 137.00 employees. See our rating of the largest employees — is NEKTAR THERAPEUTICS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEKTAR THERAPEUTICS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEKTAR THERAPEUTICS stock shows the buy signal. See more of NEKTAR THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NEKTAR THERAPEUTICS future price: according to them, NKTR price has a max estimate of 84.78 MXN and a min estimate of 16.96 MXN. Read a more detailed NEKTAR THERAPEUTICS forecast: see what analysts think of NEKTAR THERAPEUTICS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEKTAR THERAPEUTICS EBITDA is ‪−2.16 B‬ MXN, and current EBITDA margin is −143.82%. See more stats in NEKTAR THERAPEUTICS financial statements.